Analyzing RYTHM (RYM) & Its Rivals
by Amy Steele · The Cerbat GemRYTHM (NASDAQ:RYM – Get Free Report) is one of 903 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare RYTHM to similar businesses based on the strength of its valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.
Risk & Volatility
RYTHM has a beta of 9.44, meaning that its share price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s rivals have a beta of -3.17, meaning that their average share price is 417% less volatile than the S&P 500.
Profitability
This table compares RYTHM and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RYTHM | -6.20% | -12.57% | -2.60% |
| RYTHM Competitors | -2,299.87% | -222.98% | -17.45% |
Insider & Institutional Ownership
6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for RYTHM and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
| RYTHM Competitors | 7586 | 13648 | 25433 | 998 | 2.42 |
As a group, “Pharmaceuticals” companies have a potential upside of 30.14%. Given RYTHM’s rivals stronger consensus rating and higher probable upside, analysts clearly believe RYTHM has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares RYTHM and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| RYTHM | $17.28 million | -$33.26 million | -2.44 |
| RYTHM Competitors | $4.51 billion | $3.17 billion | 547.15 |
RYTHM’s rivals have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
RYTHM rivals beat RYTHM on 9 of the 13 factors compared.
About RYTHM
Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.